


# PRODUCT INFORMATION



## Nafarelin (acetate)

Item No. 24070

**CAS Registry No.:** 76932-60-0  
**Formal Name:** 6-[3-(2-naphthalenyl)-D-alanine]-luteinizing hormone-releasing factor (swine) acetate  
**MF:** C<sub>66</sub>H<sub>83</sub>N<sub>17</sub>O<sub>13</sub> • XC<sub>2</sub>H<sub>4</sub>O<sub>2</sub>  
**FW:** 1,322.5  
**Purity:** ≥95%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Nafarelin (acetate) is supplied as a solid. A stock solution may be made by dissolving the nafarelin (acetate) in the solvent of choice, which should be purged with an inert gas. Nafarelin (acetate) is slightly soluble in DMSO and methanol. Nafarelin (acetate) is also slightly soluble in water.

### Description

Nafarelin is an agonist of gonadotropin-releasing hormone (GNRH).<sup>1-3</sup> It is a long-acting agent that, after an initial increase in sex hormone levels, decreases the level of circulating gonadotropins and sex hormones. *In vivo*, nafarelin (0.5-2.0 µg/kg, s.c.) reduces plasma levels of luteinizing hormone and testosterone (Item Nos. 15645 | ISO60154) as well as testicular volume, sperm count, sperm motility, and duration of ejaculation in male dogs.<sup>1</sup> Nafarelin (32 µg/animal per day) inhibits estrus in female beagle dogs.<sup>2</sup> It also reduces the volume of endometrial tissue in a rat model of endometriosis.<sup>3</sup> Formulations containing nafarelin have been used in the treatment of endometriosis and central precocious puberty.

### References

1. Vickery, B.H., McRae, G.I., Briones, W.V., *et al.* Dose-response studies on male reproductive parameters in dogs with nafarelin acetate, a potent LHRH agonist. *J. Androl.* **6(1)**, 53-60 (1985).
2. McRae, G.I., Roberts, B.B., Worden, A.C., *et al.* Long-term reversible suppression of oestrus in bitches with nafarelin acetate, a potent LHRH agonist. *J. Reprod. Fertil.* **74(2)**, 389-397 (1985).
3. Mizutani, T., Sakata, M., and Terakawa, N. Effect of gonadotropin-releasing hormone agonists, nafarelin, buserelin, and leuprolide, on experimentally induced endometriosis in the rat. *Int. J. Fertil. Menopausal Stud.* **40(2)**, 106-111 (1995).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM